Cross-country variations in the reporting of psychotic symptoms among sub-Saharan African adults: A psychometric evaluation of the Psychosis Screening Questionnaire

Background : Self-reporting of psychotic symptoms varies significantly between cultures and ethnic groups. Yet, limited validated screening instruments are available to capture such differences in the African continent. Methodology : Among 9,059 individuals participating as controls in a multi-country case–control study of the genetic causes of psychosis, we evaluated the psychometric properties of the Psychosis Screening Questionnaire (PSQ). We applied multi-group confirmatory factor analysis and item response theory to assess item parameters. Results : The overall positive endorsement of at least one item assessing psychotic symptoms on the PSQ was 9.7%, with variability among countries (Uganda 13.7%, South Africa 11%, Kenya 10.2%, and Ethiopia 2.8%). A unidimensional model demonstrated good fit for the PSQ (root mean square error of approximation = 0.009; comparative fit index = 0.997; and Tucker-Lewis Index = 0.995). Hypomania had the weakest association with single latent factor (standardized factor loading 0.62). Sequential multi-group confirmatory factor analysis demonstrated that PSQ items were measured in equivalent ways across the four countries. PSQ items gave more information at higher levels of psychosis, with hypomania giving the least discriminating information. Limitations : Participants were recruited from general medical facilities, so findings may not be generalizable to the general population. Conclusion : The PSQ demonstrated a unidimensional factor structure in these samples. Items were measured equivalently across all study settings, suggesting that differences in prevalence of psychotic symptoms between countries were less likely to represent measurement artifact. The PSQ is more reliable in screening for psychosis in individuals with higher degrees of psychotic experiences—hypomania excluded—and might decrease the false-positive rate from mild nonspecific psychotic experiences

Infant peri-exposure prophylaxis for 12 months to eliminate breastfeeding transmission of HIV-1 in Africa. The ANRS 12174 cohort

International audienceThe efficacy of infant peri-exposure prophylaxis (PreP) to prevent HIV-1 postnatal transmission has never been assessed for the entirerecommended period of breastfeeding (12 months).The ANRS 12174 study is a randomised controlled trial comparing the efficacy and safety of lopinavir/ritonavir versus lamivudine to preventHIV-1 postnatal transmission in breastfeeding children born to HIV-1-infected mothers not eligible for ART (CD4 count above 350cells/mL) during breastfeeding (maximum 50 weeks). HIV-uninfected children aged 7 days were randomised for either drug in a 1:1 ratio.Infant HIV-infection status was assessed at week 6, 14, 26, 38 and 50 using HIV-1 DNA PCR. The study has completed enrolment in April2012 in Burkina Faso, Uganda, Zambia and South Africa. We report the current postnatal HIV-1 transmission rate and HIV-1 free survivalin the cohort among children aged 50 weeks or more in July 2012.By the end of July 2012, of 1273 children enrolled in the trial, 788 were aged 50 weeks or older. During this period, 8 transmissions occurredrepresenting a cumulative transmission rate of 1.1% (95%CI: 0.6-2.2). Interestingly, 6/8 transmissions occurred after 6 months ofbreastfeeding. Overall, 188 severe adverse events (grade 3 or more, DAIDS classification) and 22 deaths were identified. None were consideredattributable to the study drugs. The overall cumulative mortality was 3.0% (95%CI: 2.0-4.5) and HIV-1-free survival was 96.0%(95%CI: 94.3-97.2).Infant PreP is an efficacious strategy that could contribute to the elimination of HIV-1 transmission by breastfeeding